Nestlé Strengthens Health Science Business
Nestlé has successfully completed its acquisition of Aimmune Therapeutics in a deal which valued the US-based biotech business at about $2.6 billion. Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc’s global pharmaceutical business.
“Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives,” says Greg Behar, CEO of NHSc. “Aimmune’s PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it’s only the beginning. Aimmune’s pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally.”
Aimmune will continue to be run from Brisbane, California. Andrew Oxtoby has been named as Aimmune’s President & CEO, along with a new executive leadership team.Andrew Oxtoby was previously Aimmune’s Chief Commercial Officer.
The development program for Aimmune — which consists of the potential use of PALFORZIA in toddlers and adults, multiple clinical development programs in other allergies, and the development of the monoclonal antibody AlMab7195 — will proceed as planned.
